Si-Ware Partners with Eurofins Agro to Explore Applications for Feeds and Forages

MENLO PARK, CA (November 30, 2022) –Si-Ware Systems, the creator of the NeoSpectra material analysis platform, today announced a collaboration with Eurofins Agro to investigate the application of the NeoSpectra platform to their analytical portfolio, including feed and forage applications.

Eurofins Agro is part of Eurofins Scientific, an internationally growing laboratory and contract research organization with over 61,000 personnel in 59 countries, operating in940 laboratories. With over 100 years of experience, Eurofins Agro has laboratories worldwide with a mission to contribute to healthy, viable, and sustainable farming and growing.

The announced collaboration leverages the world-class laboratory and NIR application expertise of Eurofins Agro with the versatility and high performance of the innovative NeoSpectra platform to explore options to add increased value to customers in the near future.

"NeoSpectra is bringing a lot of opportunities to the table in terms of flexibility in feed and forage applications. We’re excited to see how this will bring additional value to our services," Martijn van Oostrum, Team Leader Development at Eurofins Agro.

"I'm really excited to be working on this project with Eurofins Agro and bringing the lab-grade performance models and the NeoSpectra platform advantages to multiple users in labs, “added Mostafa Medhat, VP of Product and Customer Happiness at Si-Ware. “Eurofins Agro’s mission to contribute to healthy, viable, and sustainable farming and growing is completely aligned with our goals at NeoSpectra, and we look forward to adding value to the services that help growers and processors feed the world in a sustainable and profitable way.”

Future developments from this collaboration will be released by both companies.

‍

####

‍

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000staff across a decentralised and entrepreneurial network of 940 laboratories in59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020 and 2021,Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISINFR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

‍